Lower price erosion in the current fiscal year is expected to help Sun Pharma, India’s largest drugmaker, to post a gradual improvement in sales from its US business. Analysts estimate that price erosion for the generic space, which was at 13-15 per cent last year, is expected to come down to about 8-10 per cent in FY19.
While the company, which derives 35 per cent of its consolidated sales from the US market, reported a 3 per cent fall over the year-ago quarter, on a sequential basis the US sales grew 12 per cent. The improvement, first in at least four quarters, was on ...
TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST Rs
Key stories on business-standard.com are available to premium subscribers only.
Already a premium subscriber? LOGIN NOW
First Published: Sun, May 27 2018. 20:20 IST
